Synonym
MR39; MR 39; MR-39;
IUPAC/Chemical Name
(S)-N-((1-(3-chloro-4-fluorophenyl)cyclopropyl)methyl)-3-(4-cyanophenyl)-2-(3-(4-fluorophenyl)ureido)propanamide
InChi Key
LIRJUPFMKLVNMO-DEOSSOPVSA-N
InChi Code
InChI=1S/C27H23ClF2N4O2/c28-22-14-19(5-10-23(22)30)27(11-12-27)16-32-25(35)24(13-17-1-3-18(15-31)4-2-17)34-26(36)33-21-8-6-20(29)7-9-21/h1-10,14,24H,11-13,16H2,(H,32,35)(H2,33,34,36)/t24-/m0/s1
SMILES Code
FC1=CC=C(NC(N[C@@H](CC2=CC=C(C#N)C=C2)C(NCC3(CC3)C4=CC(Cl)=C(F)C=C4)=O)=O)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
508.95
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cristiano C, Volpicelli F, Crispino M, Lacivita E, Russo R, Leopoldo M, Calignano A, Perrone-Capano C. Behavioral, Anti-Inflammatory, and Neuroprotective Effects of a Novel FPR2 Agonist in Two Mouse Models of Autism. Pharmaceuticals (Basel). 2022 Jan 28;15(2):161. doi: 10.3390/ph15020161. PMID: 35215274; PMCID: PMC8875614.
2: Tylek K, Trojan E, Leśkiewicz M, Regulska M, Bryniarska N, Curzytek K, Lacivita E, Leopoldo M, Basta-Kaim A. Time-Dependent Protective and Pro- Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways. Cells. 2021 Sep 9;10(9):2373. doi: 10.3390/cells10092373. PMID: 34572022; PMCID: PMC8472089.
3: Trojan E, Tylek K, Schröder N, Kahl I, Brandenburg LO, Mastromarino M, Leopoldo M, Basta-Kaim A, Lacivita E. The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Improves Ex Vivo and In Vivo Amyloid Beta (1-42)-Induced Neuroinflammation in Mouse Models of Alzheimer's Disease. Mol Neurobiol. 2021 Dec;58(12):6203-6221. doi: 10.1007/s12035-021-02543-2. Epub 2021 Sep 1. PMID: 34468933; PMCID: PMC8639560.
4: Trojan E, Tylek K, Leśkiewicz M, Lasoń W, Brandenburg LO, Leopoldo M, Lacivita E, Basta-Kaim A. The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Exhibits Anti-Inflammatory Activity in LPS-Stimulated Organotypic Hippocampal Cultures. Cells. 2021 Jun 17;10(6):1524. doi: 10.3390/cells10061524. PMID: 34204273; PMCID: PMC8235773.
